Elizabeth H.z. Thompson - 29 Jul 2026 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Reporting relationship: EVP, Head of Research & Dev
Issuer ticker: ACAD
Reported as of: 29 Jul 2026
Net transaction value: -$432,663
SEC form: 4
Accepted by SEC: 31 Jul 2026, 18:00:17 UTC
Prior SEC filing: 26 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact

Key filing fact

Elizabeth H.z. Thompson filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 31 Jul 2026.

Key facts

This page summarizes Elizabeth H.z. Thompson's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 31 Jul 2026, 18:00.

Change

Previous filing in this sequence was filed on 26 Mar 2026.
Current net transaction value: -$432,663.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001861477 Primary reporting owner

Thompson Elizabeth H.Z.

Relationship: EVP, Head of Research & Dev
Address: C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO
Signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact
Signature date: 31 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACAD transaction

Common Stock

Options Exercise

Transaction value
Shares: +32,272
Change %: +984%
Price
Shares after: 35,552
Date: 29 Jul 2026
Ownership: Direct
Footnotes: F1

ACAD transaction

Common Stock

Sale

Transaction value: $431,354
Shares: -16,508
Change %: -46%
Price: $26.13
Shares after: 19,044
Date: 30 Jul 2026
Ownership: Direct
Footnotes: F2

ACAD transaction

Common Stock

Sale

Transaction value: $1,308
Shares: -50
Change %: -0.26%
Price: $26.17
Shares after: 18,994
Date: 30 Jul 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACAD transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -32,272
Change %: -50%
Price: $0.000000^*
Shares after: 32,272
Date: 29 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,272
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Footnote F3

50% of the restricted stock units vested on July 29, 2026 and 25% vest on each of July 29, 2027 and July 29, 2028.